Results 71 to 80 of about 2,011 (166)

Insights into antitrypanosomal drug mode-of-action from cytology-based profiling.

PLoS Neglected Tropical Diseases, 2018
Chemotherapy continues to have a major impact on reducing the burden of disease caused by trypanosomatids. Unfortunately though, the mode-of-action (MoA) of antitrypanosomal drugs typically remains unclear or only partially characterised.
James A Thomas, Nicola Baker, Sebastian Hutchinson, Caia Dominicus, Anna Trenaman, Lucy Glover, Sam Alsford, David Horn   +7 more
doaj   +1 more source

The detection and treatment of human African trypanosomiasis

Research and Reports in Tropical Medicine, 2012
Bernard Bouteille,1 Alain Buguet21Laboratory of Parasitology, Dupuytren University Hospital of Limoges, France; 2Polyclinic Marie-Louise Poto-Djembo, Pointe-Noire, CongoAbstract: Human African trypanosomiasis (HAT) is caused by the injection of ...
Bouteille B, Buguet A
doaj  

Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis

Research and Reports in Tropical Medicine, 2012
Jose R Franco,1 Pere P Simarro,1 Abdoulaye Diarra,2 Jose A Ruiz-Postigo,3 Mireille Samo,1 Jean G Jannin11World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland; 2World Health ...
Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Samo M, Jannin JG   +5 more
doaj  

Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial. [PDF]

Cancer Prev Res (Phila)
Morgan DR, Dominguez RL, Norwood DA, Montalvan-Sanchez EE, Piazuelo MB, Rodriguez-Murillo A, Delgado AG, Hernandez-Marrero J, Gonzalez-Pons M, Beasley TM, Cruz-Correa M, Wilson KT.   +11 more
europepmc   +1 more source

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. [PDF]

J Clin Oncol
Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C, Levin VA.   +28 more
europepmc   +1 more source

Targeted Therapies in Neuroblastoma: A History and a View to the Future. [PDF]

Cancers (Basel)
Shah N.
europepmc   +1 more source

Combination of Intense Pulsed Light and Topical Eflornithine Therapy Versus Intense Pulsed Light Alone in the Treatment of Idiopathic Facial Hirsutism: A Randomized Controlled Trial. [PDF]

Cureus
Nawaz MU, Baig MB, Shahid SM, Nawaz MH, Inayat S, Dawood M.   +5 more
europepmc   +1 more source

Eflornithine for the Chemoprevention of Luminal Gastrointestinal Neoplasms: A Systematic Review. [PDF]

Gastroenterology Res
Godoy A, Montalvan-Sanchez D, Principe-Meneses FS, Riva-Moscoso A, Sierra L, Erazo G, Avila C, Ramirez-Rojas M, Giron R, Guifarro DA.   +9 more
europepmc   +1 more source

Use of fexinidazole in gambiense human African trypanosomiasis: a retrospective analysis of cases treated in Lui Hospital, South Sudan (2018-2024). [PDF]

Infection
Mariotti F, Paggi R, Basilico M, Pettenuzzo S, Benson GS, Amodu A, Zammarchi L, Rusconi S, Scanagatta C, Putoto G, Dacquino S, Gelormino E.   +11 more
europepmc   +1 more source

A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis. [PDF]

Antimicrob Agents Chemother
Pérez Antón E, Dujeancourt-Henry A, Rotureau B, Glover L.   +3 more
europepmc   +1 more source